HPV58 (Human Papilloma Virus) type therapeutic composite genetic vaccine and construction method thereof

A gene vaccine and therapeutic technology, applied in the field of human papillomavirus type 58 therapeutic compound gene vaccine and its construction, can solve the problems of ignoring antigenicity, ineffective cervical tissue treatment, virus escape, etc., and achieve good safety and effectiveness , improve anti-tumor function, and enhance the effect of immune recognition

Inactive Publication Date: 2011-11-02
广西医科大学附属肿瘤医院
View PDF4 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, this type of vaccine has the following problems: since the L1 and L2 capsid proteins are not expressed in cervical cancer and precancerous lesion tissues, the above-mentioned vaccines can only be used to prevent HPV58 infection, but for cervical tissue that has already been infected or pathological changes Ineffective treatment
This type of vaccine has the following problems: Although E1 and E2 proteins are involved in the replication of virus episomes and the transcription of early viral genes, they may be good target antigens in the early stage of infection, but the expression levels of E1 and...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • HPV58 (Human Papilloma Virus) type therapeutic composite genetic vaccine and construction method thereof
  • HPV58 (Human Papilloma Virus) type therapeutic composite genetic vaccine and construction method thereof
  • HPV58 (Human Papilloma Virus) type therapeutic composite genetic vaccine and construction method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0026] Study on the Safety and Effectiveness of HPV58 Vaccine

[0027] One, PVAX1-HPV58mE6E7FcGB vaccine construction (such as Figure 5 )

[0028] The two keys of immunotherapy are suitable antigen and efficient carrier. In terms of antigen selection, since the early genes E6 and E7 of HPV are necessary to maintain its malignant phenotype, they are expressed in all stages of tumor development from the beginning of virus infection to the advanced stage of cancer, which can induce the body to produce and maintain strong The specific CTL with viral antigen as the target molecule is still the target antigen commonly selected for the development of HPV therapeutic vaccines so far. When designing the antigen, the inventor first removed the termination codes of the HPV58 E6 and E7 genes, and fused the E6 and E7 genes into the HPV58E6E7 fusion gene. Since HPV E6 and E7 are oncoproteins, viral DNA may integrate into the host cell genome, induce malignant transformation of cells, an...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an HPV58 (Human Papilloma Virus) type therapeutic composite genetic vaccine and a construction method thereof. In the vaccine, an HPV58 type E6/E7 fusion gene is used as a target antigen, and GM/B7 is used as an antigen adjuvant, wherein stop codes of HPV58 type E6 and E7 genes are removed from the HPV58 type E6/E7 fusion gene; and meanwhile, amino acids of 50, 63 and 106 on E6 protein and the amino acids 24, 26 and 92 on E7 protein are mutated into glycines. The HPV58 type therapeutic composite genetic vaccine provided by the invention has high safety, strong immunity and an ideal anti-tumor effect, provides a better choice for treating cervical carcinoma and precancerous lesion related to the HPV58 type infection, and is particularly suitable for HPV58 type highly-infective cervical carcinoma patients in China and Asia.

Description

technical field [0001] The invention relates to the field of prevention and treatment of cervical cancer, in particular to a human papillomavirus type 58 (hereinafter referred to as HPV58) therapeutic compound gene vaccine and a construction method thereof. Background technique [0002] Cervical cancer is one of the common gynecological malignancies, and its incidence rate ranks second among female malignancies, second only to breast cancer. There are about 131,500 new cases of cervical cancer in my country every year, accounting for 28.8% of the total number of new cases of cervical cancer in the world, and about 50,000 patients die of cervical cancer every year, most of which are located in economically underdeveloped western regions such as Guangxi. At present, traditional methods such as surgery, radiotherapy, and chemotherapy are not effective for patients with advanced cervical cancer, and the 5-year survival rate is only 50%. Etiological studies of cervical cancer ha...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K48/00A61K39/12A61K39/39C12N15/62A61P35/00
Inventor 王鹤于继云李力
Owner 广西医科大学附属肿瘤医院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap